



ABOUT THE PCF-VA PARTNERSHIP

- On November 29, 2016, the United States Department of Veterans Affairs (VA) and the Prostate Cancer Foundation (PCF) entered into a multi-year partnership.

GOAL: “NO VETERAN LEFT BEHIND FOR PRECISION BREAKTHROUGHS”

- Deliver precision oncology to all 100% of veterans battling prostate cancer by 2023.
- The partnership establishes 20 PCF-VA Centers of Excellence through a public-private collaboration to optimally address urgent health challenges for U.S. veterans facing cancer.
- The ultimate goal is to save lives, delivering new genomic treatments and cures for veterans battling prostate cancer. PCF is providing a roadmap for the application of cutting-edge precision medicine solutions for all forms of cancer in the VA and globally.



VA



U.S. Department
of Veterans Affairs

THE NEED

- 1 in 9 men will be diagnosed with prostate cancer. There are nearly 4 million men living with prostate cancer in the U.S. **Lack of access to big data on which to base predictive analytics is the greatest impediment to progress.**
- Among U.S. veterans, prostate cancer is the most frequently diagnosed cancer, accounting for $\frac{1}{3}$ of all VA cancer cases. Veterans with prostate cancer also lack consistent access to precision oncology. According to the Department of Veterans Affairs' Central Cancer Registry, **prostate cancer remains the largest oncology burden in the VA health system.**

PCF AND THE VA – CURING TOGETHER

- PCF makes strategic, targeted investments in the most promising research ideas available, attracting brilliant individuals and teams of scientists early in their careers. **PCF's approach has resulted in a 52% decline in the U.S. prostate cancer death rate since 1993; more than 1.5 million lives have been saved from prostate cancer in the U.S. alone; 9 new FDA-approved medicines developed in the last 9 years; and multiple discoveries in prostate cancer now extend to saving lives in 73 other forms of cancer.**
- The VA, in turn, will make their anonymized electronic medical record data available to PCF researchers. **The VA possesses one of the richest and largest data sets of patients in existence, with more than 9 million records – including nearly 1 million whole genome sequences ready for big-data analysis.**

LEVERAGING THE PCF EFFECT

- PCF has raised more than \$800 million, providing funding to more than 4,500 researchers at more than 220 cancer centers and universities and extending the PCF Global Research Enterprise to 22 countries.
- PCF's **unique venture philanthropy** approach to medical research funding sets us apart from the typical non-profit organization. Smart philanthropic investors know this – and quietly but effectively make real differences in the battle against prostate cancer by supporting PCF.
- PCF leverages investments.** A conservative assessment of leverage on philanthropic investment through PCF is 31:1. When innovative ideas and their discoveries become viable, projects receive millions in additional investment from biopharmaceutical companies and through government funding, in turn pushing treatment advances to market.

PCF research projects are selected through a competitive peer-review process by the world's top prostate cancer researchers. These innovative ideas are often too early in their formulation to receive traditional biopharmaceutical investment or government funding, and PCF bridges that "earliest innovation" gap. Through project monitoring, progress reports, and site visits, PCF ensures benchmarks are achieved while connecting researchers across the globe to share scientific data in real time.

A PRECISION MEDICINE ROADMAP FOR ALL AMERICA'S VETERANS WITH CANCER

A \$50 Million Campaign Poised to Shape Medical History

PCF's **multi-year Veterans Health Initiative** will provide U.S. veterans the same or better precision oncology care as our most fortunate private citizens, as well as the same access to genomics research and clinical trials.


Precision oncology allows for treatments of cancer defined by genetic signature rather than simply affected organ(s). And given the VA's leadership in the area of tele-medicine, advances from this program will be scalable and available beyond any geographic limitations. The VA has committed to sustainable funding after the full work force at the Centers of Excellence has been launched. By 2025, the model in prostate cancer will then be expanded to over 100 other forms of cancer cared for in the VA.

PCF is offering philanthropists the opportunity to support our courageous veterans battling prostate cancer through a network of Centers of Excellence in Precision Oncology at VA facilities around the country.

PCF-VA NETWORK OF 20 PRECISION ONCOLOGY CENTERS OF EXCELLENCE

- ② Ann Arbor, MI – The Stewart J. Rahr Foundation Precision Oncology Center of Excellence at the VA Ann Arbor
- ② Boston, MA – The Blavatnik Family Foundation Precision Oncology Center of Excellence at VA Boston Healthcare System, Harvard Medical School, Dana-Farber Cancer Institute NCI-CCC
- ② Bronx, NY – The Blavatnik Family Foundation Precision Oncology Center of Excellence at the VA Bronx
- ② Chicago, IL – The Robert Frederick Smith Precision Oncology Center of Excellence at the VA Chicago
- ② Durham, NC – The Michael and Lori Milken Family Foundation Precision Oncology Center of Excellence at the VA Durham
- ② Los Angeles, CA – The David Geffen Foundation Precision Oncology Center of Excellence at the West Los Angeles VA
- ② Manhattan, NY – The John and Daria Barry Foundation Precision Oncology Center of Excellence at the VA Manhattan
- ② Philadelphia, PA – The Jonathan and Plum Simons Precision Oncology Center of Excellence at the VA Philadelphia
- ② Portland, OR – VA Portland Health Care System Oregon Health & Science University and Knight Cancer Institute NCI-CCC
- ② Seattle, WA – The Stephen J. Cloobeck Precision Oncology Center of Excellence at the VA Puget Sound
- ② Tampa and Bay Pines, FL – The John and Daria Barry Foundation Precision Oncology Center of Excellence at the VA Tampa and VA Bay Pines
- ② Washington, DC – The Edward P. Evans Foundation Precision Oncology Center of Excellence at the VA Washington, DC

- Baltimore, MD – Baltimore VA Medical Center Johns Hopkins University (JHU) School of Medicine and Sidney Kimmel Cancer Center NCI-CCC and University of Maryland Greenebaum Comprehensive Cancer Center NCI-CCC
- Dallas, TX – Dallas VA Medical Center University of Texas Southwestern Medical Center and Harold C. Simmons Comprehensive Cancer Center NCI-CCC
- Denver, CO – The Rocky Mountain Regional Veterans Affairs Medical Center The University of Colorado School of Medicine Cancer Center NCI-CCC
- Houston, TX – The Michael E. DeBakey VA Medical Center Baylor College of Medicine Dan L. Duncan Comprehensive Cancer Center NCI-CCC, MD Anderson Cancer Center NCI-CCC, University of Texas at Houston School of Medicine
- Minneapolis, MN – Minneapolis VA Health Care System University of Minnesota School of Medicine and Masonic Cancer Center NCI-CCC
- Phoenix, AZ – Phoenix VA Health Care System The University of Arizona School of Medicine and Cancer Center NCI-CC
- Salt Lake City, UT – VA Salt Lake City Health Care System University of Utah School of Medicine and Huntsman Cancer Institute NCI-CCC
- San Francisco, CA – San Francisco VA Health Care System University of California San Francisco School of Medicine and Helen Diller Family Comprehensive Cancer Center NCI-CCC



This partnership is changing the lives of 500,000 veterans suffering from prostate cancer, providing the level of care their service to our nation demands. By combining PCF's private sector approach with the scale and mission of the VA, we will save the lives of thousands of veterans. Join us – we cure together.